Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC

This article was originally published here

The designation enables to use of JNJ-6372 to treat patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has advanced on

The post Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply